In experimental NSCLC, the antitumour benefits of AQP3-targeting shRNA were found, as shown by the suppression of AQP3 ablation for lung cancer development and longer life in preclinical experiments [117]. Here, AQP3 is linked to non-small cell lung carcinoma.